Abstract | INTRODUCTION: MATERIALS AND METHODS: A randomized crossover study was conducted in 13 type 2 diabetes patients with CKD who maintained glycosylated hemoglobin (HbA1c) levels at <9 % by diet and exercise and had estimated glomerular filtration rates (eGFRs) <60 ml/min 1.73 m2. They were treated with teneligliptin at 20 mg/day or linagliptin at 5 mg/day for 6 days then switched to the other agent for another 6 days. CGM was performed before and during treatment. The primary outcome was changes in mean amplitude of glucose excursions (MAGE). RESULTS: Mean MAGE was 83.8 ± 34.0 and 82.6 ± 32.6 [±standard deviation (SD)] during treatment with linagliptin and teneligliptin, respectively, with no significant difference between agents. The two agents showed comparable beneficial effects on 24-h mean sensor glucose levels and area under the curve for sensor glucose levels ≥180 mg/dl (AUC ≥180), and their use was associated with comparable incidence of hypoglycemia. CONCLUSIONS:
|
Authors | Kenichi Tanaka, Yosuke Okada, Hiroko Mori, Yoshifumi Inada, Kanako Suzuka, Kohei Uriu, Yoshiya Tanaka |
Journal | Diabetology international
(Diabetol Int)
Vol. 7
Issue 4
Pg. 368-374
(Dec 2016)
ISSN: 2190-1678 [Print] Japan |
PMID | 30603288
(Publication Type: Journal Article)
|